Cardiff Oncology Inc (NASDAQ:CRDF) has a beta value of 1.73 and has seen 0.39 million shares traded in the recent trading session. The company, currently valued at $204.57M, closed the recent trade at $3.08 per share which meant it lost -$0.06 on the day or -2.07% during that session. The CRDF stock price is -107.14% off its 52-week high price of $6.38 and 34.74% above the 52-week low of $2.01. If we look at the company’s 10-day average daily trading volume, we find that it stood at 1.18 million shares traded. The 3-month trading volume is 1.10 million shares.
The consensus among analysts is that Cardiff Oncology Inc (CRDF) is Buy stock at the moment, with a recommendation rating of 1.00. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 0 out of 1 have rated it as a Hold, with 1 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is -0.2.
Cardiff Oncology Inc (NASDAQ:CRDF) trade information
Sporting -2.07% in the red today, the stock has traded in the red over the last five days, with the highest price hit on recent trading when the CRDF stock price touched $3.08 or saw a rise of 19.16%. Year-to-date, Cardiff Oncology Inc shares have moved -29.15%, while the 5-day performance has seen it change -19.08%. Over the past 30 days, the shares of Cardiff Oncology Inc (NASDAQ:CRDF) have changed -19.40%. Short interest in the company has seen 13.34 million shares shorted with days to cover at 11.41.
Cardiff Oncology Inc (CRDF) estimates and forecasts
The company’s shares have gained 11.01% over the past 6 months. Revenue growth from the last financial year stood is estimated to be -51.20%.
6 analysts offering their estimates for the company have set an average revenue estimate of 87.5k for the current quarter. 6 have an estimated revenue figure of 87.5k for the next ending quarter. Year-ago sales stood 205k and 163k respectively for this quarter and the next, and analysts expect sales will shrink by -57.32% for the current quarter and -51.20% for the next.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was 19.36% over the past 5 years. Earnings growth for 2025 is a modest 16.18% while over the next 5 years, the company’s earnings are expected to decrease by -7.70%.
CRDF Dividends
Cardiff Oncology Inc is expected to release its next earnings report on 2025-Feb-26 this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Cardiff Oncology Inc (NASDAQ:CRDF)’s Major holders
Insiders own 5.62% of the company shares, while shares held by institutions stand at 39.03% with a share float percentage of 41.35%. Investors are also buoyed by the number of investors in a company, with Cardiff Oncology Inc having a total of 142.0 institutions that hold shares in the company. The top two institutional holders are BLACKROCK INC. with over 2.63 million shares worth more than $5.84 million. As of 2024-06-30, BLACKROCK INC. held 5.8637% of shares outstanding.
The other major institutional holder is VANGUARD GROUP INC, with the holding of over 2.14 million shares as of 2024-06-30. The firm’s total holdings are worth over $4.74 million and represent 4.7816% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and iShares Trust-iShares Russell 2000 ETF. As of Dec 31, 2024, the former fund manager holds about 1.89% shares in the company for having 1.25 shares of worth $3.85 million while later fund manager owns 1.08 shares of worth $3.33 million as of Feb 28, 2025, which makes it owner of about 1.63% of company’s outstanding stock.
